Clinical and Electrophysiological Predictors of Arrhythmic Recurrence in Patients With Paroxysmal AF Undergoing First Ablation Procedure of AF by Pulmonary Vein Isolation

Launched by CENTRO CARDIOLOGICO MONZINO · Oct 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying patients with paroxysmal atrial fibrillation (AF), a condition where the heart's upper chambers beat irregularly and can cause symptoms like palpitations or fatigue. The goal is to identify factors that might predict whether patients will experience a return of AF after undergoing an ablation procedure, which is a treatment aimed at restoring a normal heart rhythm. Researchers want to understand how different characteristics—like a patient's age, gender, heart size, and the length of time they’ve had AF—can affect the success of this treatment.

To be eligible for this trial, participants must be between 65 and 75 years old and have a medical reason to undergo AF ablation. They should also be receiving appropriate blood-thinning medication to prevent blood clots. However, individuals who have had previous AF treatments, have certain heart conditions, or are pregnant will not be able to participate. Those who join the trial can expect close monitoring and support throughout the process, helping to improve understanding of how to better predict and manage AF in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with indication for AF ablation
• • Adequate anticoagulation therapy according to CHADs VASC
• Exclusion Criteria:
• • patients who had already undergo an AF ablation procedure
• • Presence of intracavitary thrombus
• • Ejection fraction \<35%
• • Pregnancy
• • Hematologic contraindications to ionizing radiation exposure
• • Congenital heart diseases
• • Cardiac Surgery \< 1month
• • Uncontrolled heart failure
• • Valvular disease
• • Contraindications to general anesthesia